| Schedule of changes in carrying amount of goodwill [Text Block] |
The
changes in the carrying amount of goodwill for the six months ended
July 3, 2011, follow:
|
(millions of dollars)
|
|
Primary
Care
|
|
|
Specialty
Care
and
Oncology
|
|
|
Established
Products
and
Emerging
Markets
|
|
|
Animal
Health
and
Consumer
Healthcare
|
|
|
Nutrition
|
|
|
To
be
allocated(a)
|
|
|
Total
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2010
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
2,449 |
|
|
$ |
496 |
|
|
$ |
40,983 |
|
|
$ |
43,928 |
|
|
Additions(b)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
791 |
|
|
|
791 |
|
|
Other(c)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16 |
|
|
|
10 |
|
|
|
362 |
|
|
|
388 |
|
|
Balance,
July 3, 2011
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
2,465 |
|
|
$ |
506 |
|
|
$ |
42,136 |
|
|
$ |
45,107 |
|
|
(a)
|
The
amount to be allocated includes the former Biopharmaceutical
goodwill (see below), as well as newly acquired goodwill from our
acquisition of King, for which the allocation to reporting units is
pending (see Note
3. Acquisition of King Pharmaceuticals, Inc. for additional
information).
|
|
(b)
|
Relates
to our acquisition of King and is subject to change until we
complete the recording of the assets acquired and liabilities
assumed from King (see Note 3. Acquisition of King
Pharmaceuticals, Inc.). The allocation of King goodwill
among our reporting units has not yet been completed, but will be
completed within one year of the acquisition date.
|
|
(c)
|
Primarily
reflects the impact of foreign exchange.
|
|
| Schedule of identifiable intangible assets [Text Block] |
The
components of identifiable intangible assets follow:
| |
|
July
3, 2011
|
|
|
December
31, 2010
|
|
|
(millions of dollars)
|
|
Gross
Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Identifiable
Intangible
Assets,
less
Accumulated
Amortization
|
|
|
Gross
Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Identifiable
Intangible
Assets,
less
Accumulated
Amortization
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finite-lived
intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Developed
technology rights
|
|
$ |
71,354 |
|
|
$ |
(29,608 |
) |
|
$ |
41,746 |
|
|
$ |
68,432 |
|
|
$ |
(26,223 |
) |
|
$ |
42,209 |
|
|
Brands
|
|
|
1,710 |
|
|
|
(649 |
) |
|
|
1,061 |
|
|
|
1,626 |
|
|
|
(607 |
) |
|
|
1,019 |
|
|
License
agreements
|
|
|
582 |
|
|
|
(254 |
) |
|
|
328 |
|
|
|
637 |
|
|
|
(248 |
) |
|
|
389 |
|
|
Trademarks
and other
|
|
|
522 |
|
|
|
(322 |
) |
|
|
200 |
|
|
|
533 |
|
|
|
(324 |
) |
|
|
209 |
|
|
Total
amortized finite-lived intangible assets
|
|
|
74,168 |
|
|
|
(30,833 |
) |
|
|
43,335 |
|
|
|
71,228 |
|
|
|
(27,402 |
) |
|
|
43,826 |
|
|
Indefinite-lived
intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brands
|
|
|
10,285 |
|
|
|
— |
|
|
|
10,285 |
|
|
|
10,219 |
|
|
|
— |
|
|
|
10,219 |
|
|
In-process
research and development
|
|
|
3,366 |
|
|
|
— |
|
|
|
3,366 |
|
|
|
3,438 |
|
|
|
— |
|
|
|
3,438 |
|
|
Trademarks
|
|
|
73 |
|
|
|
— |
|
|
|
73 |
|
|
|
72 |
|
|
|
— |
|
|
|
72 |
|
|
Total
indefinite-lived intangible assets
|
|
|
13,724 |
|
|
|
— |
|
|
|
13,724 |
|
|
|
13,729 |
|
|
|
— |
|
|
|
13,729 |
|
|
Total
identifiable intangible assets(a)
|
|
$ |
87,892 |
|
|
$ |
(30,833 |
) |
|
$ |
57,059 |
|
|
$ |
84,957 |
|
|
$ |
(27,402 |
) |
|
$ |
57,555 |
|
|
(a)
|
The
decrease is primarily related to amortization as well as impairment
charges (see Note 6. Other
(Income)/Deductions—Net)
of intangible assets, partially offset by the assets acquired as
part of the acquisition of King (see Note 3. Acquisition of King
Pharmaceuticals, Inc.) and the impact of foreign
exchange.
|
|